TCR2 Therapeutics Inc. (NASDAQ:TCRR) saw a downside of -2.00% to close Friday at $8.34 after subtracting -$0.17 on the day. The 5-day average trading volume is 622,000 shares of the company’s common stock. It has gained $9.24 in the past week and touched a new high 1 time within the past 5 days. An average of 1,209,805 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 696,396.
TCRR’s 1-month performance is -52.45% or -$9.20 on its low of $8.13 reached on 10/01/21. The company’s shares have touched a 52-week low of $8.34 and high of $35.86, with the stock’s rally to the 52-week high happening on 01/14/21. YTD, TCRR has lost -73.04% or -$22.59 and has reached a new high 5 times. However, the current price is down -76.74%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Dec 14, 292 days have gone by since the last insider trading activity for TCR2 Therapeutics Inc. (TCRR). Somaiya Mayur Ian (Chief Financial Officer) most recently sold 2,000 shares at $35.00 per share on Dec 14. This transaction cost the insider $70,000. Chief Financial Officer, Somaiya Mayur Ian, sold 3,666 shares at a price of $30.00 on Nov 17. Then, on Nov 12, Chief Scientific Officer Hofmeister Robert sold 20,000 shares at a price of $25.10 per share. This transaction amounted to $502,000.
TCR2 Therapeutics Inc. (TCRR) has a trailing price-to-earnings (P/E) ratio of 33.74 for the broader industry and 32.48 for the sector, meaning that investors are optimistic about the stock’s future prospects. TCRR stock has a beta of 0.00. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 0.97.
TCR2 Therapeutics Inc.’s quick ratio for the period ended June 29 was 21.80, with the current ratio over the same period at 21.80 meaning that TCRR stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.00. The firm’s gross profit as reported stood at $1.74 million against revenue of $68.7 million.
The effectiveness of a company’s management is also important for investors when it comes to determining the potential profitability of the investment. TCR2 Therapeutics Inc.’s return on assets over the past 12 months stands at -25.50%, while its return on equity (ROE) trailing 12 months is -27.80%. In comparison, the average ROE for the broader industry over the past year is -36.91.
For the quarterly period ending June 29 this year, TCR2 Therapeutics Inc.’s cash and short-term investments amounted to $68.55 million against total debt of $27.64 million. Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected TCRR to announce -$0.59 per share in earnings in its latest quarter, but it posted -$0.64, representing a -8.50% surprise. EBITDA for the quarter stood at more than -$23.6 million. TCRR stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 39.25 million, with total debt at $27.64 million. Shareholders hold equity totaling $38.18 million
Let’s look briefly at TCR2 Therapeutics Inc. (TCRR) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 01 October was 17.80% to suggest the stock is trending oversold, with historical volatility in this time period at 38.78%.
The stock’s 5-day moving average is $8.60, reflecting a -3.92% or -$0.34 change from its current price. TCRR is currently trading -53.09% above its 20-day SMA, -56.88% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -37.43% and -70.49% respectively.
Stochastic %K and %D was 1.29% and 1.31% and the average true range (ATR) pointed at 0.88. The RSI (14) points at 23.63%, while the 14-day stochastic is at 2.01% with the period’s ATR at 0.95. The stock’s 9-day MACD Oscillator is pointing at -0.40 and -2.10 on the 14-day charts.
In the most recent analyst report for TCR2 Therapeutics Inc. (NASDAQ: TCRR), Wedbush downgraded it to a Neutral rating. They previously had an Outperform rating on the stock. Analysts offering their rating for TCRR stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate TCRR as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 8 have offered a “buy” rating.
What is TCRR’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $11.00 and a high of $51.00, with their median price target at $29.00. Looking at these predictions, the average price target given by analysts is for TCR2 Therapeutics Inc. (TCRR) stock is $31.89.